ArticleProtoplasma2026
Gene expression and metabolic regulation of carotenoid and withanolide biosynthetic pathways in Withania somnifera with emphasis on FPPS-mediated regulation.
Article in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Withania somnifera (Ashwagandha) is a prominent medicinal plant, valued for pharmacologically active secondary metabolites, particularly withanolides and carotenoids. In this study a comprehensive overview of the gene expression and metabolic regulation of withanolide and carotenoid biosynthetic pathways was undertaken across vegetative and reproductive tissues. Transcript profiling of 22 genes involved in these pathways revealed differential expression patterns, particularly highlighting Farnesyl Pyrophosphate Synthase (FPPS) as a key flux-regulating enzyme. In silico characterization and phylogenetic analysis confirmed the high conservation of FPPS isoforms. Transient overexpression of WsFPPS2 in W. somnifera leaves resulted in increased withanolide content, indicating that WsFPPS2 acts as a key upstream enzyme for the withanolide biosynthetic pathway. These findings underscore the metabolic sensitivity of the mevalonate pathway and point to FPPS as a strategic target for metabolic engineering. This work lays the foundation for enhancing the production of high-value metabolites in W. somnifera via metabolic engineering and synthetic biology interventions.
Indexed as
Identifiers
42171742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.